Non-opioid Pain Treatment Market Growth, Size, Trends Analysis - By Drug Class, By Pain, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Non-opioid Pain Treatment Market Introduction and Overview

According to SPER market research, 'Global Non-opioid Pain Treatment Market Size- By Drug Class, By Pain, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Non-opioid Pain Treatment Market is predicted to reach 104.89 billion by 2034 with a CAGR of 7.53%.

Non-opioid pain treatments are pharmacological therapies that alleviate pain without relying on opioids, which can lead to addiction and other negative consequences. This group mostly includes NSAIDs, analgesics, antidepressants, and other pharmaceuticals. Non-opioid analgesics are becoming increasingly popular due to their safety and efficacy in treating both acute and chronic pain.

Restraints: The side effects of non-opioid medications are creating significant barriers to the growth of the non-opioid pain management market. Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), the most popular type of nonopioid painkiller available, has been linked to an increased risk of gastrointestinal, renal, and cardiovascular complications. NSAIDs can induce gastritis, ulcers, and in severe cases, gastrointestinal bleeding.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Drug Class, By Pain, By Route of Administration, By Distribution Channel.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Novartis AG, Teva Pharmaceutical Industries Limited, Dr. Reddys Laboratories Ltd, Sun Pharmaceutical Industries Ltd, GSK plc, Pfizer Inc, Perrigo Company plc, LNK International, Inc, Cipla Inc, Johnson & Johnson Services, Inc, Pacira Pharmaceuticals, Inc, Pierrel. and others.

Non-opioid Pain Treatment Market Segmentation:

By Drug Class: Based on the Drug Class, Global Non-opioid Pain Treatment Market is segmented as; NSAIDs, Acetaminophen, Local Anesthetics, Other Drug Class.

By Pain: Based on the Pain, Global Non-opioid Pain Treatment Market is segmented as; Post-operative Pain, Cancer Pain, Chronic Pain, Other Pain.

By Route of Administration: Based on the Route of Administration, Global Non-opioid Pain Treatment Market is segmented as; Oral, Topical, Injectable, Other Route of Administration.

By Distribution Channel: Based on the Distribution Channel, Global Route of Administration Market is segmented as. Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA2578

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Non-opioid Pain Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Non-opioid Pain Treatment Market

7. Global Non-opioid Pain Treatment Market, By Drug Class (USD Million) 2021-2034

7.1. NSAIDs
- 7.1.1. Non Selective NSAIDs
- 7.1.2. Selective COX-2 Inhibitors
7.2. Acetaminophen
7.3. Local Anesthetics
7.4. Other Drug Class

8. Global Non-opioid Pain Treatment Market, By Pain (USD Million) 2021-2034

8.1. Post-operative Pain
8.2. Cancer Pain
8.3. Chronic Pain
8.4. Other Pain

9. Global Non-opioid Pain Treatment Market, By Route of Administration (USD Million) 2021-2034

9.1. Oral
9.2. Topical
9.3. Injectable
9.4. Other Route of Administration

10. Global Non-opioid Pain Treatment Market, By Distribution Channel (USD Million) 2021-2034

10.1. Hospital Pharmacies
10.2. Retail Pharmacies
10.3. Online Pharmacies

11. Global Non-opioid Pain Treatment Market, (USD Million) 2021-2034

11.1. Global Non-opioid Pain Treatment Market Size and Market Share

12. Global Non-opioid Pain Treatment Market, By Region, (USD Million) 2021-2034

12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America

13. Company Profile

13.1. Novartis AG
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. Teva Pharmaceutical Industries Limited
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. Dr. Reddys Laboratories Ltd
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. Sun Pharmaceutical Industries Ltd
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. GSK plc
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. Pfizer Inc
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. Perrigo Company plc
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. LNK International, Inc
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. Cipla Inc
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. Johnson & Johnson Services, Inc
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. Pacira Pharmaceuticals, Inc
- 13.11.1. Company details
- 13.11.2. Financial outlook
- 13.11.3. Product summary
- 13.11.4. Recent developments
13.12. Pierrel
- 13.12.1. Company details
- 13.12.2. Financial outlook
- 13.12.3. Product summary
- 13.12.4. Recent developments
13.13. Others